



Europe

Teva Pharmaceuticals Europe B.V.

**EFPIA Disclosure Code  
2019 Self-Certification Letter  
Teva Pharmaceuticals Europe BV**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Teva Pharmaceutical Europe BV works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and HCPs. These collaborations are essential in addressing patient needs. Industry and HCPs collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs and HCOs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Teva Pharmaceutical Europe BV hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2018 have been reported in application of the EFPIA Disclosure Code following key principles:

**Disclosure scope:**

Teva Pharmaceutical Europe BV certifies that its disclosures of ToVs:

- Have been completed in each EFPIA country where Teva Pharmaceuticals Europe BV operates,
- include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA as well as associated national codes/clarifications,
- are further described in the respective country's Methodological Note, and
- may contain minor discrepancies resulting from the sale, transition, and timing of marketing authorization transfers of Teva's women's health business to Theramex.

**Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes**

Teva Pharmaceutical Europe BV certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Disclosure Code).

**Teva Pharmaceuticals Europe B.V.**

Piet Heinkade 107, P.O. Box 16416, 1001 RM AMSTERDAM - The Netherlands  
Phone: +31(0)20 2193 000 – Fax: +31(0)20 2193 299 [www.tevapharm.com](http://www.tevapharm.com)



Europe

Teva Pharmaceuticals Europe B.V.

(continued)

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons**

Teva Pharmaceutical Europe BV certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

### **Ensuring compliance with data privacy obligations**

Teva Pharmaceutical Europe BV also certifies that its disclosure complies with relevant data privacy obligations.

Date: June 28, 2019

Name of signatory: Richard Daniell

Position in the Company: Executive Vice President  
Teva Pharmaceuticals Europe BV

Signature:

**Richard Daniell  
Executive Vice President  
Europe Commercial**

### **Teva Pharmaceuticals Europe B.V.**

Computerweg 10, P.O. Box 43011, 3540 AA UTRECHT - The Netherlands  
Phone: +31(0)346 290 200 – Fax: +31(0)346 290 299 [www.tevapharm.com](http://www.tevapharm.com)

Chamber of Commerce Utrecht 30110625, VAT NO. NL 003 973 190 B01,  
Bank: ABN-AMRO IBAN: NL98 ABNA 0241487862, BIC: ABNANL2AXXX